NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Forecast & News

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.15. The biopharmaceutical company had revenue of $8.04 million for the quarter, compared to analysts' expectations of $11.70 million. Dicerna Pharmaceuticals had a negative net margin of 541.24% and a negative return on equity of 58.92%. View Dicerna Pharmaceuticals' Earnings History.

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 equities research analysts have issued 1 year price targets for Dicerna Pharmaceuticals' shares. Their forecasts range from $18.00 to $50.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $31.57 in the next twelve months. This suggests a possible upside of 57.5% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.

Media stories about DRNA stock have been trending neutral this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a news impact score of 0.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,840,000 shares, an increase of 6.4% from the January 15th total of 2,670,000 shares. Based on an average daily trading volume, of 925,400 shares, the days-to-cover ratio is currently 3.1 days. Currently, 5.1% of the shares of the stock are short sold. View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Evotec (EVTCY), Global Blood Therapeutics (GBT), FibroGen (FGEN), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), SAGE Therapeutics (SAGE), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS) and Agios Pharmaceuticals (AGIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), TG Therapeutics (TGTX), Amarin (AMRN), Array Biopharma (ARRY), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Arrowhead Pharmaceuticals (ARWR) and Catalyst Pharmaceuticals (CPRX).

Dicerna Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (5.96%), EcoR1 Capital LLC (5.30%), UBS Group AG (3.20%), Bridger Management LLC (2.90%), Eagle Asset Management Inc. (2.57%) and State Street Corp (2.42%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Brian K Halak, Dennis Langer, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

DRNA stock was sold by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, Bridger Management LLC, EcoR1 Capital LLC, UBS Group AG, Sofinnova Investments Inc., Emerald Advisers LLC, State Street Corp and Emerald Mutual Fund Advisers Trust. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky. View Insider Buying and Selling for Dicerna Pharmaceuticals.

DRNA stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Driehaus Capital Management LLC, Marshall Wace LLP, Renaissance Technologies LLC, Parkman Healthcare Partners LLC, Marshall Wace North America L.P., Connor Clark & Lunn Investment Management Ltd. and EAM Investors LLC. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $20.04.

Dicerna Pharmaceuticals has a market capitalization of $1.37 billion and generates $6.18 million in revenue each year. The biopharmaceutical company earns $-88,850,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.View Additional Information About Dicerna Pharmaceuticals.

The official website for Dicerna Pharmaceuticals is http://www.dicerna.com/.

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]